ct-95: sourced relationships with 1 company · 1 clinical trial tracked.
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could ct-95 → CNTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
No additional listed-company sponsor is linked.
| Company | Dated record stage |
|---|---|
| Context Therapeutics Inc. (CNTX) Mesothelin-Expressing Tumors | Phase 1 |
Context reported discontinuing internal development of CT-95 on August 5, 2026. The older registry’s Recruiting status remains dated to its own publication; current recruitment is unknown.
Context internal development; registry status has its own source date · 2026-08-05 · SEC source
Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression
Primary endpoint: Determine the MTD or RD of CT-95 [Safety and Tolerability]
ct-95 has dated SEC/FDA relationship records for Context Therapeutics Inc..
BioSniper tracks 1 clinical trial involving ct-95.